Switch theme
Sign up to access all valuation multiples
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
1935
23.6K+
LTM Revenue $3.2B
LTM EBITDA $832M
$12.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cipla has a last 12-month revenue of $3.2B and a last 12-month EBITDA of $832M.
In the most recent fiscal year, Cipla achieved revenue of $3.0B and an EBITDA of $780M.
Cipla expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cipla valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.6B | $3.0B | XXX | XXX | XXX |
| Gross Profit | $1.4B | $1.6B | XXX | XXX | XXX |
| Gross Margin | 55% | 53% | XXX | XXX | XXX |
| EBITDA | $600M | $780M | XXX | XXX | XXX |
| EBITDA Margin | 23% | 26% | XXX | XXX | XXX |
| Net Profit | $292M | $325M | XXX | XXX | XXX |
| Net Margin | 11% | 11% | XXX | XXX | XXX |
| Net Debt | $17.0M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Cipla's stock price is INR 1463 (or $17).
Cipla has current market cap of INR 1.18T (or $13.7B), and EV of INR 1.10T (or $12.8B).
See Cipla trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.8B | $13.7B | XXX | XXX | XXX | XXX | $0.70 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Cipla has market cap of $13.7B and EV of $12.8B.
Cipla's trades at 4.0x LTM EV/Revenue multiple, and 15.3x LTM EBITDA.
Analysts estimate Cipla's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cipla and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $12.8B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | 15.6x | XXX | XXX | XXX |
| P/E | 25.2x | XXX | XXX | XXX |
| P/E/Growth | 4.3x | XXX | XXX | XXX |
| EV/FCF | 29.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCipla's NTM/LTM revenue growth is 9%
Cipla's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Cipla's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cipla's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cipla and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 30% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 35% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 41% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cipla acquired XXX companies to date.
Last acquisition by Cipla was XXXXXXXX, XXXXX XXXXX XXXXXX . Cipla acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Cipla founded? | Cipla was founded in 1935. |
| Where is Cipla headquartered? | Cipla is headquartered in India. |
| How many employees does Cipla have? | As of today, Cipla has 23.6K+ employees. |
| Who is the CEO of Cipla? | Cipla's CEO is Mr. Umang Vohra. |
| Is Cipla publicy listed? | Yes, Cipla is a public company listed on BOM. |
| What is the stock symbol of Cipla? | Cipla trades under 500087 ticker. |
| When did Cipla go public? | Cipla went public in 1992. |
| Who are competitors of Cipla? | Similar companies to Cipla include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Cipla? | Cipla's current market cap is $13.7B |
| What is the current revenue of Cipla? | Cipla's last 12-month revenue is $3.2B. |
| What is the current EBITDA of Cipla? | Cipla's last 12-month EBITDA is $832M. |
| What is the current EV/Revenue multiple of Cipla? | Current revenue multiple of Cipla is 4.0x. |
| What is the current EV/EBITDA multiple of Cipla? | Current EBITDA multiple of Cipla is 15.3x. |
| What is the current revenue growth of Cipla? | Cipla revenue growth between 2023 and 2024 was 13%. |
| Is Cipla profitable? | Yes, Cipla is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
